Brief: Knight Therapeutics Announces Regulatory Submission For Tafasitamab In Brazil
06/10/2022 23:18
Oct 6 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES REGULATORY SUBMISSION FOR
TAFASITAMAB IN BRAZIL
* KNIGHT THERAPEUTICS INC - UNITED MEDICAL HAS SUBMITTED
MARKETING
AUTHORIZATION APPLICATION FOR TAFASITAMAB IN COMBINATION WITH
LENALIDOMIDE TO ANVISA
Source text for Eikon: ID:nGNX7bmW2X
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil